Usme-Ciro José A, Méndez Jairo A, Laiton Katherine D, Páez Andrés
a Grupo de Virología; Subdirección Red Nacional de Laboratorios ; Dirección de Redes en Salud Pública; Instituto Nacional de Salud ; Bogotá DC , Colombia.
Hum Vaccin Immunother. 2014;10(9):2674-8. doi: 10.4161/hv.29563. Epub 2014 Nov 19.
Dengue is a major threat for public health in tropical and subtropical countries around the world. In the absence of a licensed vaccine and effective antiviral therapies, control measures have been based on education activities and vector elimination. Current efforts for developing a vaccine are both promising and troubling. At the advent of the introduction of a tetravalent dengue vaccine, molecular surveillance of the circulating genotypes in different geographical regions has gained considerable importance. A growing body of in vitro, preclinical, and clinical phase studies suggest that vaccine conferred protection in a geographical area could depends on the coincidence of the dengue virus genotypes included in the vaccine and those circulating. In this review we present the state-of-the-art in this field, highlighting the need of deeper knowledge on neutralizing immune response for making decisions about future vaccine approval and the potential need for different vaccine composition for regional administration.
登革热对全球热带和亚热带国家的公共卫生构成重大威胁。由于缺乏许可疫苗和有效的抗病毒疗法,控制措施一直基于教育活动和病媒消除。目前开发疫苗的努力既充满希望又令人担忧。在引入四价登革热疫苗之际,对不同地理区域循环基因型的分子监测变得相当重要。越来越多的体外、临床前和临床阶段研究表明,疫苗在一个地理区域提供的保护可能取决于疫苗中包含的登革热病毒基因型与流行基因型的匹配情况。在本综述中,我们介绍了该领域的最新进展,强调了在决定未来疫苗批准时深入了解中和免疫反应的必要性,以及区域给药可能需要不同疫苗组成的潜在需求。